Meeting
2019 ASCO Annual Meeting
CALLA: Efficacy and safety of durvalumab with and following concurrent chemoradiotherapy (CCRT) versus CCRT alone in women with locally advanced cervical cancer-A phase III, randomized, double-blind, multicenter study.
Authors
Bradley J. Monk
Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph’s Hospital, Phoenix, AZ
Bradley J. Monk , Jyoti Mayadev , Ana T Nunes , Alicja Dabrowska Brown , Michelle Marcovitz , Mark C. Lanasa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Cervical Cancer
Clinical Trial Registration Number
NCT03830866
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS5597)
DOI
10.1200/JCO.2019.37.15_suppl.TPS5597
Abstract #
TPS5597
Poster Bd #
418b
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).
First Author: John M. Varlotto
First Author: Matt D. Galsky
Poster
2019 ASCO Annual Meeting
A phase III, randomized, open label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine+cisplatin (G+C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MIBC) (NIAGARA).
First Author: Thomas Powles
Poster
2019 Genitourinary Cancers Symposium
A phase III, randomized, open-label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SoC) chemotherapy and durvalumab in combination with tremelimumab and soc chemotherapy versus soc chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).
First Author: Matt D. Galsky